Study Showing Superiority News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
EXTON, Pa., Feb. 10, 2021 /PRNewswire/  Despite the potential for setbacks brought forth by the COVID-19 pandemic, Amgen recently reported strong year-over-year growth for their newly acquired psoriasis (PSO) and psoriatic arthritis (PsA) agent, Otezla.
1 In late 2019, the brand was sold to Amgen in order to clear the path for Bristol-Myers Squibb s acquisition of Celgene, considering future regulatory conflicts with BMS pipeline psoriasis drug, deucravacitinib, an oral TYK2 inhibitor anticipated to be in direct competition with Otezla.
Amgen s purchase of Otezla strengthens the company s long-standing immunology portfolio, including TNF inhibitor, Enbrel, which has been approved in RA for over two decades and also holds a dual PSO/PsA indication. However, according to ongoing feedback collected from US dermatologists and rheumatologists included in Spherix s ....

Novarti Cosentyx , Eli Lilly Taltz , Bob Bradway , Kristen Henn , Eli Lilly , Bristol Myers Squibb , Abbvie Skyrizi , Dermatologic Siliq , Janssen Tremfya , Our Services , Amgen Inc , Business Development , Realtime Dynamix , Ortho Dermatologic Siliq , Sun Dermatology , Special Topix , Multi Specialty Impact , Realworld Dynamix , Will Amgen , Time Dynamix , World Dynamix , Global Insights , Earnings Conference Call , Myers Squibb Announces Positive Topline Results , Second Pivotal Phase , Study Showing Superiority ,